Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05521269 | Dose Study of ANX1502 in Healthy Volunteers | PHASE1 | COMPLETED | 135 | — | — | Jun 27, 2022 | Nov 19, 2024 | Dec 27, 2024 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| ANX1502 SAD | EXPERIMENTAL | Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo. |
| ANX1502 MAD | EXPERIMENTAL | Participants will be administrated multiple oral doses of ANX1502 at various ascending dose levels or matching placebo for 14 days. |
| Name | Type | Description |
|---|---|---|
| ANX1502 | DRUG | ANX1502 is a prodrug of ANX1439. |
| Placebo | DRUG | Placebo comparator. |
Key Inclusion Criteria: * Must be healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments (including supine blood pressure, supine pulse rate, respiration rate, and temporal body temperature), 12-lead electrocardiogram (ECG), and laborato...